<DOC>
	<DOCNO>NCT01074996</DOCNO>
	<brief_summary>A randomized , open-label , multicenter , phase II study compare efficacy S-1 S-1 plus Leucovorin second line treatment gemcitabine-refractory patient inoperable advanced pancreatic cancers，investigate correlation efficacy expression thymidylate synthase , dihydropyrimidine dehydrogenase orotate phosphoribosyltransferase</brief_summary>
	<brief_title>Study S-1 Second Line Treatment Advanced Pancreatic Cancers</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>1 . Histologically confirm inoperable APC . 2 . Failure one prior gemcitabinebased regimen require , chemotherapy use radiation sensitizer adjuvant locally advance setting consider prior regimen . Patients receive last adjuvant gemcitabinebased chemotherapy le ( equal ) six month enrol study . 3 . Disease measurable Response Evaluation Criteria Solid Tumors ( RECIST ) criterion . 4 . Age ≥18 year old . 5 . ECOG performance status 0 1 . 6 . Written inform consent able comply protocol . 1 . Local ( Stage IA IIB ) pancreatic cancer locally advance ( stage III ) pancreatic cancer . Patients relapse metastatic disease , initial diagnosis local disease enrol study . 2 . Previous adjuvant radiotherapy pancreatic cancer , except patient progressive lesion outside radiation port complete radiotherapy least 6 month prior study entry . 3 . More ( equal ) six month since last adjuvant chemotherapy . Adjuvant therapy without gemcitabine base adjuvant therapy allow . Patient must recover treatment related toxicity prior enrollment must document evidence disease progression ( metastatic ) follow prior chemotherapy . 4 . No previous gemcitabinebased therapy inoperable APC . 5 . Other primary tumour ( include primary brain tumour ) within last 5 year prior enrollment , except adequately treat carcinoma situ cervix basal cell skin cancer . 6 . Evidence spinal cord compression current evidence central nervous system ( CNS ) metastases . 7 . History evidence upon neurological exam CNS disease ( unless adequately treat standard medical therapy ) e.g . uncontrolled seizure . 8 . Inability take oral medication , prior surgical procedure affect absorption result requirement intravenous alimentation parenteral nutrition lipid , and/or active peptic ulcer disease 9 . Pregnant lactating female . Serum pregnancy test assess within 7 day prior study treatment start , within 14 day confirmatory urine pregnancy test within 7 day prior study treatment start 10 . Men woman childbearing potential ( &lt; 2 year last menstruation ) use effective mean contraception ( oral contraceptive , intrauterine contraceptive device , barrier method contraception conjunction spermicidal jelly surgically sterile ) 11 . Current recent ( within 30 day prior start study treatment ) treatment another investigational drug participation another investigational study 12 . Evidence disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug , patient high risk treatment complication 13 . Known hypersensitivity study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Pancreatic cancer</keyword>
	<keyword>S-1</keyword>
	<keyword>S-1 plus Leucovorin</keyword>
	<keyword>second-line therapy</keyword>
</DOC>